The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Boehringer Ingelheim Pharmaceuticals, Inc. is initiating a drug recall of 1 lot(s) of JARDIANCE® Tablets 25mg to the Wholesale and Retail Pharmacy level. This recall is being conducted with the knowledge of the Food and Drug Administration. A portion of the 30-count product lot mentioned above is labelled as JARDIANCE® Tablets 25mg 90 count. As only the pre-printed quantity of tablets indicated on the label is incorrect, all batch variable data is correct, and the label reflects the correct product and strength, it is not likely to cause any health risk to patients.

Product	NDC No.	Lot No.	Exp. Data	Ship Dates to Wholesalers
JARDIANCE® Tablets 25 mg (Empagliflozin)				
90 Tablets per bottle	0597-0153- 90	E61835	JUN 2025	02/13/2023 - 02/17/2023
·	90			02/17/2025
JARDIANCE® Tablets 25 mg				
(Empagliflozin)				
	0597-0153-	E61835	JUN 2025	02/13/2023 -
30 Tablets per bottle	30	101033	JOIN 2023	02/17/2023